Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Enoyl-CoA hydratase, mitochondrial (ECHS1), is an enzyme located in the mitochondrial matrix that catalyzes the second step in the beta-oxidation pathway of fatty acid metabolism. Specifically, it hydrates 2-trans-enoyl-CoA intermediates to L-3-hydroxyacyl-CoA thioesters, facilitating the continued degradation of fatty acids for energy production[1][5]. ECHS1 acts primarily on short- and medium-chain fatty acyl-CoA esters (C4–C16)[5]. Deficiency in ECHS1 is associated with severe mitochondrial disorders, especially a form of Leigh Syndrome, due to defective oxidative phosphorylation (OXPHOS) and impaired tricarboxylic acid cycle and mitochondrial bioenergetics[2]. ECHS1 also interacts with key signaling proteins such as STAT3 and has been implicated in cancer biology and apoptosis, particularly in liver diseases like hepatocellular carcinoma[1][2]. The enzyme belongs to the hydratase/isomerase superfamily and is essential for normal energy homeostasis in humans.
Irreversible inhibition via covalent adduct formation with ECHS1 (experimental inhibitors).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Enoyl-CoA hydratase, mitochondrial (ECHS1).